Deutetrabenazine - Generic Drug Details

What are the generic sources for deutetrabenazine and what is the scope of freedom to operate?

Deutetrabenazine is the generic ingredient in three branded drugs marketed by Teva, Teva Branded Pharm, and Aurobindo Pharma Ltd, and is included in three NDAs. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deutetrabenazine has one hundred and seventy-six patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for deutetrabenazine

International Patents:	176
US Patents:	15
Tradenames:	3
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	17
Patent Applications:	38
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for deutetrabenazine
What excipients (inactive ingredients) are in deutetrabenazine?	deutetrabenazine excipients list
DailyMed Link:	deutetrabenazine at DailyMed

Recent Clinical Trials for deutetrabenazine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Teva Pharmaceuticals USA	PHASE4
University Hospitals Cleveland Medical Center	PHASE4
Neurocrine Biosciences	PHASE4

See all deutetrabenazine clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for deutetrabenazine

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for DEUTETRABENAZINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUSTEDO XR	Extended-release Tablets	deutetrabenazine	6 mg, 12 mg and 24 mg	216354	1	2026-03-02
AUSTEDO	Tablets	deutetrabenazine	6 mg, 9 mg and 12 mg	208082	2	2021-04-05

US Patents and Regulatory Information for deutetrabenazine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-006	May 29, 2024		RX	Yes	No					Y
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-002	Apr 3, 2017		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-001	Feb 17, 2023		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-001	Feb 17, 2023		RX	Yes	No					Y
Aurobindo Pharma Ltd	DEUTETRABENAZINE	deutetrabenazine	TABLET;ORAL	215971-002	Dec 26, 2024		DISCN	No	No

International Patents for deutetrabenazine

Country	Patent Number	Title	Estimated Expiration
Taiwan	201840317	Analogs of DEUTETRABENAZINE, their preparation and use
Brazil	PI0913457
South Korea	20210149246	비정상적 불수의 운동 장애의 치료 방법 (METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS)
Japan	7419571
Chile	2017002223

Deutetrabenazine Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for DEUTETRABENAZINE?

Deutetrabenazine, marketed as Austedo, is an FDA-approved drug for treating chorea associated with Huntington’s disease and tardive dyskinesia. Its market is influenced by several factors:

• Disease prevalence: Huntington’s disease affects approximately 3 to 7 per 100,000 people globally, with higher rates among specific populations (e.g., Western countries)[1]. Tardive dyskinesia prevalence varies with long-term antipsychotic use, estimated at 4-20% in treated populations[2].

• Competitive landscape: Austedo faces competition from tetrabenazine (Xenazine), approved in 2008 for Huntington’s chorea, and other symptomatic drugs like antipsychotics. The introduction of generic tetrabenazine pressures patent-protected Austedo prices.

• Regulatory landscape: Deutetrabenazine received FDA approval in 2017, with subsequent approvals in Europe. Patent expiry looms, with patent protection until 2024-2026, exposing the drug to generic competition.

• Market penetration: As an alternative to tetrabenazine, Austedo offers a potentially improved side-effect profile. US sales reached approximately $350 million in 2022, representing steady growth driven by increased physician adoption[3].

• Pricing and reimbursement: The drug’s pricing in the US ranged from $7,000 to $8,000 per month in 2022. Insurance coverage and formulary inclusion are critical for revenue continuity.

• Research and pipeline activity: Ongoing trials for off-label uses or combination therapies could expand the drug’s indications, influencing future market size.

What Is the Financial Trajectory for DEUTETRABENAZINE?

Deutetrabenazine’s revenue has shown a steady upward pattern since market approval, with notable factors:

• Revenue growth: US sales grew from approximately $290 million in 2020 to $350 million in 2022, reflecting higher prescription volumes and expanded adoption[3].

• Profitability prospects: As a patented drug, gross margins are expected to be high, typically exceeding 80%. Patent expiration, scheduled around 2024-2026, may lead to revenue erosion unless generic versions emerge earlier or strategic partnerships develop.

• Impact of generic competition: The expiration of patents paves the way for generics, which can significantly reduce brand-name drug prices. Historical data from tetrabenazine indicates a price drop of up to 60% upon generic entry[4].

• Potential for pipeline growth: The company developing deutetrabenazine might seek approval for other neurological conditions or new formulations, diversifying revenue sources and offsetting patent loss.

• Cost considerations: Development costs for future formulations or indications remain high, with clinical trial expenses typically ranging from $50 million to $150 million per indication[5].

• Market risks: Patent challenges, regulatory delays, and changes in reimbursement policies could impact financial performance.

How Do Patent Timelines and Competitive Factors Affect Future Revenue?

Patent expirations around 2024-2026 will be critical:

Year	Patent Expiry	Potential Impact
2024	Primary patent	Entry of generics, price declines, revenue decrease
2025	Secondary patents	Market competition increases
2026	Market stability if no new patents	Reduction in exclusivity

Generic entry is expected to lower prices substantially, paralleling tetrabenazine’s pricing history. Without patent protection, revenue could decline by as much as 50-70%, unless new indications or formulations prolong profitability.

What Are the Key Market and Financial Risks?

• Regulatory setbacks delaying new approvals.
• Competition from existing generics and new entrants.
• Pricing pressures due to healthcare cost containment.
• Potential shifts in disease epidemiology or off-label usage patterns.
• Strategic delays in product lifecycle management or pipeline development.

Key Takeaways

• Deutetrabenazine is a brand-leading medication for Huntington’s chorea with rising sales driven by increased clinician adoption.
• The upcoming patent expirations are poised to significantly impact revenue through generic competition.
• The drug's high gross margin is vulnerable to price erosion post-patent expiry.
• Expanding indications and new formulations could offset revenue losses.
• Market and regulatory risks remain substantial but manageable with strategic planning.

FAQs

1. When will Deutetrabenazine face generic competition?
Patent protection expires around 2024-2026, after which generic versions may enter the market.

2. How does Austedo compare to tetrabenazine in efficacy and safety?
Both treat chorea in Huntington’s disease, but Austedo tends to have a more favorable side-effect profile and fewer drug interactions, contributing to its market acceptance.

3. Are there ongoing trials expanding Deutetrabenazine’s indications?
Yes, clinical trials are exploring off-label use in psychiatric disorders and other movement disorders, which may expand its market.

4. What factors could prolong Austedo’s market exclusivity?
Secondary patents, new formulations, or approved alternative indications can extend exclusivity periods.

5. How could healthcare policy changes impact future revenues?
Reimbursement reforms, price controls, or formulary restrictions could negatively influence sales trajectory.

---

Citations:

[1] Huntington’s Disease Society of America, 2022.
[2] Correll CU, et al. (2011). Tardive Dyskinesia: An Update. Current Psychiatry Reports, 13(1).
[3] IQVIA, 2022.
[4] IMS Health, 2019.
[5] DiMasi JA, et al. (2016). Innovation in the Development of Biologic Drugs. Pharm Res.